Want to see IN:EPIGRAL full AI Analyst Report?
EPIGRAL Stock Chart & Stats
₹1244.30
-₹4.30(-0.24%)
At close: 4:00 PM EST
₹1244.30
-₹4.30(-0.24%)
Day’s Range― - ―
52-Week Range₹806.20 - ₹2,114.30
Previous CloseN/A
Volume42.70K
Average Volume (3M)1.86K
Market Cap
₹42.24B
Enterprise Value₹54.46B
Total Cash (Recent Filing)₹54.60M
Total Debt (Recent Filing)₹5.72B
Price to Earnings (P/E)12.7
Beta1.47
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)76.95
Shares Outstanding43,141,340
10 Day Avg. Volume1,295
30 Day Avg. Volume1,859
Financial Highlights & Ratios
PEG Ratio-1.15
Price to Book (P/B)1.57
Price to Sales (P/S)1.40
P/FCF Ratio-535.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)75.55
Revenue Forecast (FY)₹30.05B
Bulls Say, Bears Say
Bulls Say
Strengthened Balance Sheet (low Leverage)Debt down to ~0.26x equity and expanded equity materially improve financial flexibility. This durable de-leveraging reduces refinancing risk, supports capital allocation for maintenance capex or strategic moves, and enhances resilience through industry cycles over the next 2–6 months.
Healthy Operating And Net MarginsSustained mid-teens operating and double-digit net margins indicate lasting pricing power or cost efficiency in its chemical operations. Strong margins underpin profitability across cycles, helping the company absorb raw material swings and preserve long-term cash generation potential.
Attractive Return On Equity (~15%)A ~15% ROE reflects efficient capital use and suggests the business can generate above-cost returns on invested capital. Persistently positive ROE supports reinvestment or shareholder returns and signals structural competitiveness despite recent profit compression.
Bears Say
Deteriorating Cash Generation / Negative FCFA swing to slightly negative free cash flow despite reported profits is a durable concern: it points to working-capital strain or investment outlays that reduce internal funding. Limited FCF constrains debt reduction, capex funding, and shareholder returns over the medium term.
Revenue Softness And VolatilityFlat recent revenue and volatile historic growth undermine scale economics and revenue visibility. Without consistent top-line expansion, margin recovery or durable profit growth depends on cost actions or new demand, increasing medium-term execution risk.
Margin Compression / Softer Earnings PowerMaterial margin compression signals persistent cost pressure or competitive pricing that erodes sustainable profitability. Lower margins reduce cushion for shocks and may force trade-offs between investment and returns, weakening medium-term earnings resilience.
Epigral Ltd News
EPIGRAL FAQ
What was Epigral Ltd’s price range in the past 12 months?
Epigral Ltd lowest stock price was ₹806.20 and its highest was ₹2114.30 in the past 12 months.
What is Epigral Ltd’s market cap?
Epigral Ltd’s market cap is ₹42.24B.
When is Epigral Ltd’s upcoming earnings report date?
Epigral Ltd’s upcoming earnings report date is Aug 03, 2026 which is in 22 days.
How were Epigral Ltd’s earnings last quarter?
Epigral Ltd released its earnings results on May 02, 2026. The company reported ₹18.764 earnings per share for the quarter, beating the consensus estimate of ₹14.3 by ₹4.464.
Is Epigral Ltd overvalued?
According to Wall Street analysts Epigral Ltd’s price is currently Overvalued.
Does Epigral Ltd pay dividends?
Epigral Ltd pays a Semiannually dividend of ₹5 which represents an annual dividend yield of 0.46%. See more information on Epigral Ltd dividends here
What is Epigral Ltd’s EPS estimate?
Epigral Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epigral Ltd have?
Epigral Ltd has 43,141,340 shares outstanding.
What happened to Epigral Ltd’s price movement after its last earnings report?
Epigral Ltd reported an EPS of ₹18.764 in its last earnings report, beating expectations of ₹14.3. Following the earnings report the stock price went up 0.894%.
Which hedge fund is a major shareholder of Epigral Ltd?
Currently, no hedge funds are holding shares in IN:EPIGRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Epigral Ltd
Epigral Limited operates in the chemical sector, focusing on the production and global distribution of chlor-alkali products and their associated derivatives. Its diverse product range encompasses chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash. Additionally, the company is involved in the trading of agrochemical products. Epigral caters to an extensive list of industries, including CPVC pipes and fittings, wind energy, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soaps and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. Incorporated in 2007 and based in Ahmedabad, India, the company was formerly known as Meghmani Finechem Limited until it adopted the name Epigral Limited in August 2023.
Technical Analysis
Gufic Biosciences Limited
―
Marksans Pharma Limited
―
Shilpa Medicare Limited
―
Strides Pharma Science Ltd
―
Supriya Lifescience Limited
―